WW International (WW) Q3 2025 earnings summary

Executive summary

• Emerged from Chapter 11 bankruptcy on June 24, 2025, implementing a prepackaged reorganization plan that discharged $1.6 billion in prepetition debt, reduced total debt by over 70% (~$1.1 billion), and issued new equity and a $465 million term loan facility.

• Adopted fresh start accounting, resulting in a lack of comparability between pre- and post-emergence financials.

• Laying foundation for renewed growth in weight management by integrating clinical care, medication access, and behavioral programs, with strategic initiatives including a new Menopause program and executive team expansion.

• The company operates as a single segment, focusing on Behavioral and Clinical subscription offerings, with end-of-period subscribers totaling 3.0 million, including 124,000 clinical subscribers (up 59.6% year-over-year).

• GLP-1 medications and behavioral support drive superior weight loss outcomes and improved quality of life for members.

Financial highlights

• Q3 2025 revenue was $172 million, down 10.8% year-over-year; clinical subscription revenues grew 35.3% to $26 million, while behavioral subscription revenues declined 12.0%.

• Adjusted EBITDA was $43 million with a margin of 24.9%; gross margin improved to 72.1%.

• Net loss for Q3 2025 was $58 million, with a net loss margin of 33.4% and net loss per share of $5.76.

• Ended Q3 with $170 million in cash and cash equivalents, up from $152 million in Q2.

• Marketing expenses were $48 million (28.1% of revenue), and capital expenditures were $3 million in Q3.

Outlook and guidance

• Full-year 2025 revenue guidance narrowed to $695–$700 million, with adjusted EBITDA guidance raised to $145–$150 million.

• Management expects continued disruption and competitive pressures, especially from rapid GLP-1 adoption and new market entrants.

• Gross margin expected to decline modestly in Q4 due to seasonal staffing; marketing spend to increase for peak season.

• The company believes it has sufficient liquidity to meet obligations for at least 12 months post-report.

• Expect Q3 2025 to be the low point for clinical subscribers, with growth anticipated as medication access expands.